Navmi
(Ivonescimab)Phase 3Monoclonal antibody
Ivonescimab is used to treat certain types of cancer by helping the immune system recognize and attack cancer cells that would otherwise hide from it.[1] Navmi is currently being investigated across 33 indications[3], with its most advanced program in Phase 3.[1]
Navmi is one of 621 bispecific antibody programs targeting Pancreatic Neoplasm. It is currently in Phase 3.
33
Indications
53
Total Trials
51
Active Trials
620
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 33 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Navmi
SSummit Therapeutics
Phase 3
Avastin
BBio-Thera Solutions
Preclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Megace
Bristol-Myers SquibbPreclinical
DATROWAY
Daiichi SankyoPreclinical
Effexor
WWyeth-Lederle Vaccines
Preclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Avastin
RochePreclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
First-line Treatment4 trials
Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC
Not yet recruiting·—·Phase 1/2·NCT07339839·42 enrolled
Non-Small Cell Lung Cancer3 trials
Metastatic Colorectal Cancer3 trials
Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer
Not yet recruiting·—·Phase 1·NCT07363408·30 enrolled
Locally-advanced Rectal Cancer2 trials
Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer
Not yet recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT06760520·40 enrolled
37 more indications
Ivonescimab2 trials
Chemotherapy2 trials
Brain Metastases1 trial
A Randomized Phase II Study Evaluating Upfront SRT to All Brain Metastases Followed by Ivonescimab Plus Chemotherapy Versus Upfront Ivonescimab Plus Chemotherapy in Patients With Asymptomatic Active Brain Metastases From NSCLC
Not yet recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT07234877·158 enrolled
Locally Advanced Colon Cancer1 trial
Biliary Tract Cancer1 trial
Pleural Mesothelioma1 trial
Renal Cell Cancer1 trial
Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer
Not yet recruiting·—·Phase 2·NCT07226544·31 enrolled
Salivary Gland Cancer1 trial
Esophageal Adenocarcinoma1 trial
Squamous Cell Carcinoma1 trial
Advanced NSCLC1 trial
Cutaneous Squamous Cell Carcinoma1 trial
Multiple Advanced Tumors After PD-1 Therapy Failure1 trial
Triple-Negative Breast Cancer1 trial
Renal Cell Carcinoma1 trial
Advanced Malignant Tumors1 trial
Nasopharyngeal Carcinoma1 trial
Triple Negative1 trial
Breast Cancer1 trial
Adenocarcinoma1 trial
mRNA Vaccine1 trial
TNBC1 trial
Thymus Carcinoma1 trial
Solid Tumor1 trial
Advanced Head and Neck Squamous Cell Carcinoma1 trial
Extensive-stage Small-cell Lung Cancer1 trial
NSCLC (Advanced Non-small Cell Lung Cancer)1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ivonescimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- PD-1/VEGF Bispecific[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- SSummit Therapeutics